Clinical Trial Update: Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing safety of a single dose of meningococcal ACWY conjugate vaccine across a broad age range in South Korea.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal ACWY Conjugate Vaccine (Meningococcal conjugate vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Meningococcal Disease | Phase 4 | Status: COMPLETED | Results posted: 2018-09-21